Skip to main content
Log in

Inhibition of methamphetamine sensitization by post-methamphetamine treatment with SCH 23390 or haloperidol

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Methamphetamine (2 mg/kg SC) increased ambulation in mice for about 3 h, with a peak effect at around 40 min after the administration, and its repeated administration induced sensitization. Both SCH 23390 (0.03 mg/kg SC) and haloperidol (0.4 mg/kg SC), dopamine D1 and D2 receptor antagonists, respectively, completely inhibited not only the acute stimulant effect of methamphetamine but also its sensitization when repeated methamphetamine was repeatedly combined with either of these drugs. Moreover, treatment with SCH 23390 2–5 h or haloperidol 1–5 h after each methamphetamine administration significantly antagonized methamphetamine sensitization. The maximal inhibitory effect was observed in the schedules of 3-h post-methamphetamine treatment for both drugs. However, treatments with SCH 23390 or haloperidol at 0.5 h, 6 h and 24 h after methamphetamine had no such inhibitory effect. The mice treated with SCH 23390 or haloperidol after each saline administration (the control administration for methamphetamine) did not show significant change in the sensitivity to methamphetamine. These results suggest that methamphetamine has an effect on both dopamine D1 and D2 receptors for several hours even after cessation of its acute stimulant effect, and that such an effect is involved in the induction of sensitization to the stimulant effect of methamphetamine on ambulation in mice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Beckett AH, Rowland M (1983) Urinary excretion of methamphetamine in man. Nature 206:1260–1261

    Google Scholar 

  • Demellweek C, Goudie AJ (1983) Behavioural tolerance to amphetamine and other psychostimulants: the case for considering behavioral mechanisms. Psychopharmacology 80:287–307

    Google Scholar 

  • Hirabayashi M, Alam MR (1981) Enhancing effect of methamphetamine on ambulatory activity produced by repeated administration in mice. Pharmacol Biochem Behav 15:925–932

    Google Scholar 

  • Iorio LC, Barnett A, Keitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interaction on dopaminergic synthesis. J Pharmacol Exp Ther 226:462–468

    Google Scholar 

  • Kilbey MM, Sannerud CA (1985) Models of tolerance: do they predict sensitization to the effect of psychomotor stimulant. In: Seiden LS, Balster RL (eds) Behavioral pharmacology: the current status. Alan R. Liss, New York pp 295–321

    Google Scholar 

  • Kuribara H (1994a) Can post-treatment with dopamine D1 and D2 antagonists inhibit methamphetamine and cocaine sensitizations by means of ambulatory activity in mice? Jpn J Pharmacol 64 [Supp. I] 179P

  • Kuribara H (1994b) Early post-treatment with haloperidol retards induction of methamphetamine sensitization in mice. Eur J Pharmacol 256:295–299

    Google Scholar 

  • Kuribara H (1994c) Can posttreatment with the selective dopamine D2 antagonists, YM-09151-2, inhibit induction of methamphetamine sensitization? Evaluation by ambulatory activity in mice. Pharmacol Biochem Behav 49:323–326

    Google Scholar 

  • Kuribara H, Tadokoro S (1982) Circadian variation in methamphetamine and apomorphine-induced increase in ambulatory activity in mice. Pharmacol Biochem Behav 17:1251–1256

    Google Scholar 

  • Kuribara H, Tadokoro S (1984) Circadian variation in sensitivity to methamphetamine after repeated administration in mice. Pharmacol Biochem Behav 20:247–250

    Google Scholar 

  • Kuribara H, Tadokoro S (1990) Effects of YM-09151-2, a potent and selective dopamine D2 antagonist, on the ambulation-increasing effect of methamphetamine in mice. Jpn J Pharmacol 52:489–492

    Google Scholar 

  • Kuribara H, Uchihashi Y (1993) Effects of haloperidol on the methamphetamine sensitization: assessed by ambulatory activity in mice. Jpn J Psychiatry Neurol 47:661–668

    Google Scholar 

  • Kuribara H, Uchihashi Y (1994) Effects of dopamine antagonism on methamphetamine sensitization: evaluation by ambulatory activity in mice. Pharmacol Biochem Behav 47:101–106

    Google Scholar 

  • Lewander T (1971) A mechanism for the development of tolerance to amphetamine in rats. Psychopharmacologia 21:17–31

    Google Scholar 

  • Mailman RB, Schultz DW, Lewis MH, Staples L, Rollema H, Dehaven DL (1984) SCH 23390: a selective D1 dopamine antagonist with potent D2 behavioral actions. Eur J Pharmacol 101:159–160

    Google Scholar 

  • Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157–198

    Google Scholar 

  • Tadokoro S, Kuribara H (1986) Reverse tolerance to the ambulation-increasing effect of methamphetamine in mice as an animal model of amphetamine psychosis. Psychopharmacol Bull 22:757–762

    Google Scholar 

  • Tadokoro S, Kuribara H (1990) Modification of behavioral effects of drugs after repeated administration; in particular, the reverse tolerance to amphetamines. Folia Pharmacol Jpn 95:229–238

    Google Scholar 

  • Terai M, Usuda S, Kuroiwa I, Noshiro O, Maeno H (1993) Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopmine receptors. Jpn J Pharmacol 33:749–755

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuribara, H. Inhibition of methamphetamine sensitization by post-methamphetamine treatment with SCH 23390 or haloperidol. Psychopharmacology 119, 34–38 (1995). https://doi.org/10.1007/BF02246051

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02246051

Key words

Navigation